Funding Opportunity To Detect and Report HIV-1 Drug Resistance Mutations

Funding News Edition: September 01, 2021
See more articles in this edition

If you have the expertise to develop or optimize next-generation methodologies to detect HIV-1 drug resistance (DR) mutations and rapidly disseminate the information, consider applying for a grant through the Notice of Special Interest (NOSI): HIV DR Assays and Actionable Data Dissemination Strategies.

Objective and Areas of Science

Your research efforts could improve guidance for HIV treatment and prevention programs for both individuals and populations. When you apply through this NOSI, choose one of the following responsive research areas:

  1. Highly sensitive mutation detection technologies that can be integrated into multiplex assay systems capable of simultaneous assessment of large numbers of potential mutations
  2. Point-of-care DR assays
  3. Strategies to rapidly acquire, curate, and analyze these HIV DR data and quickly disseminate results to healthcare providers and public health decision makers

Help meet a scientific need by proposing strategies applicable to countries defined as low- or middle-income by World Bank Country and Lending Groups.

The National Institute on Drug Abuse (NIDA) co-sponsors this opportunity, so check the NOSI for NIDA’s statement of interest and key contacts.

Application and Submission Information

This NOSI applies to due dates on or after September 5, 2021, and subsequent receipt dates through May 7, 2024.

Submit your application using one of the following funding opportunity announcements (FOAs) or any reissues of these FOAs through the expiration date of the NOSI.  

  • PA-20-185, NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed)
  • PA-20-195, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed)
  • RFA-AI-21-020, Early-Stage Development of Data Science Technologies for Infectious and Immune-Mediated Diseases (U01, Clinical Trial Not Allowed)
  • RFA-AI-21-021, Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated Diseases (U24, Clinical Trial Not Allowed)
  • RFA-AI-21-035, Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-Mediated Diseases (R21, Clinical Trial Not Allowed)
  • PA-21-262, PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Clinical Trial Not Allowed)
  • PA-21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44], Clinical Trial Not Allowed)

When you apply, you must follow any special requirements described in the request for applications (RFA) or parent FOA you choose. Note that NIDA does not participate in the RFAs. If you apply through a parent FOA, be sure to complete the PHS Assignment Request Form to indicate your choice of NIAID or NIDA.

Applicants must follow all instructions in the SF 424 (R&R) Application Guide and include “NOT-AI-21-056” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Direct your application questions to Dr. Usha Sharma, NIAID’s scientific/research contact listed in the Inquiries section of the NOSI.

Contact Us

Email us at for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on